2022 American Transplant Congress
Effectiveness and Limitations of PK Analysis in Optimization of Immunosuppressive Therapy for Kidney Transplantation
Division of Kidney Transplantation, Department of Surgery, Aichi Medical University, Nagakute, Japan
*Purpose: In recent years, significant improvement in organ transplant outcomes have been achieved by using multidrug therapy with several immune monitoring, but the complexity of…2022 American Transplant Congress
Effect of Schisandra Sphenanthera Extract on Pharmacokinetics of Tacrolimus in Pediatric Renal Transplant Recipients
*Purpose: Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent in adult renal transplant recipients, while its effect in pediatric recipients remains unclear. The…2022 American Transplant Congress
Tacrolimus Metabolizer Heterogeneity within Caucasian Kidney Transplant (KT) Recipients
1Intermountain Medical Center, Murray, UT, 2CareDX, South San Francisco, CA
*Purpose: Weight-based tacrolimus (T) dosing is the standard in post-transplant KT. African-Americans and Caucasians differ in their metabolizer phenotype for T. However, two morphometrically similar…2022 American Transplant Congress
Phenytoin To Expedite Sirolimus & Tacrolimus Elimination: A Case Report
*Purpose: Sirolimus (SIR), a mammalian target of rapamycin inhibitor (mTORi), may be used with or without a calcineurin inhibitor after heart transplant (HT). The anti-proliferative…2022 American Transplant Congress
Therapeutic Drug Monitoring of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Patients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Lung transplant patients are at an increased risk for invasive fungal infections and often require prophylaxis post-transplant, routinely including posaconazole at our institution. These…2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series
1University of Chicago Medicine, Chicago, IL, 2Roosevelt University, Chicago, IL
*Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »